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There is nothing new about the task of making 
difficult choices in healthcare, but policy mak-
ers in a number of countries are now addressing 
the issue of priority setting with renewed inter-
est  [1–8]. Three main reasons are discussed in the 
international literature: 
The growing evidence that the deployment of •	
current resources is far from optimal [9–14]; 
The continued growth in healthcare •	
expenditures [15]; 
Doubts about the ‘free market’ as the mecha-•	
nism of choice to allocate health sector resources 
and to determine access to services [16]. 
Of these, the increasing cost of healthcare in 
particular is making it difficult for governments 
to provide comprehensive high-quality health-
care to all citizens, irrespective of their ability 
to pay. The need to bring growing community 
aspirations and the scarcity of resources closer 
together is a common theme in the literature. 
While the importance of priority setting or 
rationing is clearly recognized (following Ham 
and Coulter [7] we use these terms interchange-
ably), the central question of how priority setting 
is to be achieved remains strongly contested.
There is a variety of priority setting approaches 
and models available. There have been several 
attempts to set priorities in public health systems; 
most noticeably in Oregon in the USA, The 
Netherlands, Sweden, Norway, New Zealand, 
Israel and the UK [1,7,17–19]. Each of these coun-
tries adopted a different approach and most 
continue to amend their processes as they strive 
to find satisfactory solutions. Some jurisdic-
tions attempted to specify ‘core services’ (The 
Netherlands, Oregon, Israel and New Zealand’s 
initial approach); some identified broad principles 
but provided little guidance to agencies on to how 
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first step is to consider what constitutes an ‘ideal’ approach to priority setting. A checklist to 
guide priority setting is presented based on guidance from economic theory, ethics and social 
justice, lessons from empirical experience and the needs of decision-makers. The checklist is 
seen as an important contribution because it is the first time that criteria from such a broad 
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setting that endeavors to be both realistic and theoretically sound. The checklist will then be 
applied to a selection of existing approaches in order to illustrate their deficiencies and to 
provide the platform for explaining the unique features of the ACE approach. A case study 
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to implement them (Norway and Sweden); while some focused 
on the development of evidence-based guidelines to ration access 
to healthcare (New Zealand and the UK). Several lessons can be 
drawn from these experiences and we return to this theme later.
In addition to this international experience, which has been 
reviewed by a number of authors [1,5,7], there is no shortage of 
normative advice offered from a range of disciplines and researchers 
on how to make the difficult choices on what services to provide 
and who to provide them to. There are models offered by behav-
ioral scientists based on achieving consensus [20–22], by epidemi-
ologists/clinicians based on needs assessment [23], by philosophers 
based on notions of social justice [24–27], by economists based on 
achieving efficiency [28–35], and there are the approaches adopted 
by administrators based on feasibility (such as historical allocation) 
that are commonly applied in real-life settings [4]. How does the 
interested decision-maker choose between these well-intentioned 
offerings? A useful first step, not often taken, is to reflect on what 
constitutes an ‘ideal’ approach to priority setting. It is with this 
important question that the history of the Australian ‘Assessing 
Cost–Effectiveness’ (ACE) approach to priority setting started. 
Checklist for evaluating priority setting approaches 
The checklist (Box 1) involves ten criteria and is based on four 
underlying rationales – ‘economic theory’, ‘ethics’, ‘empirical evi-
dence’ and ‘user considerations’. Economic theory is central as it 
is the discipline designed to offer guidance on choices in the pres-
ence of resource scarcity. Ethics is important because it provides a 
reference standard for judging societal welfare. Empirical evidence 
and user considerations are important to ensure relevance for 
decision-makers. Key conclusions on these rationales are sum-
marized below and in Box 2, and are cross-referenced to the criteria 
in Box 1. The checklist is seen as an important contribution to the 
literature on priority setting, because it is the first time, to our 
knowledge, that criteria from such a broad range of considerations 
have been brought together to develop a framework that endeavors 
to be both realistic and theoretically sound.
Rationale one: guidance from economic theory
Normative economic theories provide the theoretical rationale 
for ranking from better to worse the policies, interventions and 
associated resource allocations under consideration. For norma-
tive theories, validity rests on the realism and relevance of their 
factual and ethical assumptions. Accordingly, the assessment of 
allocative efficiency (‘value-for-money’) should be based on evalu-
ation frameworks that reflect what society truly values [36]. There 
is inevitably some overlap between ethics and economics because 
of the place of ethics in providing a reference standard for judging 
societal welfare (refer to rationale two).
The decision-making approach as the preferred 
normative foundation 
Welfarism and extra-welfarism represent the two most prominent 
approaches to normative economic ana lysis in the health sector 
and have been the focus of sustained debate and intellectual devel-
opment [29,36]. A newer framework, the decision-making approach 
(DMA), has been put forward in recent years [37]. Welfarism and 
extrawelfarism derive from two distinct conceptual foundations: 
welfare economics gives primacy to individual preferences and the 
role of the market, while the dominant form of extrawelfarism 
(Culyer’s ‘healthism’ [38]) is health-based and is conducive to a 
stronger government presence and third-party judgment on access 
by health professionals. The DMA, on the other hand, focuses 
attention on the decision-maker as the arbiter of what arguments 
should be included in the social welfare function and what weight 
should be afforded each element. 
There exist alternative ways to define and assess ‘value’ within 
the key economic notion of allocative efficiency [39–47]. Within the 
orthodox welfarist approach value is assessed using individual util-
ity; within extrawelfarism value is assessed using a measure of health 
gain. While the DMA does not in theory preclude either a welfarist 
or extrawelfarist approach to what constitutes value (as the objec-
tive function is determined by the decision-maker), in practice it 
has been closely associated with the extrawelfarist framework. The 
DMA framework also allows the inclusion of social justice issues, 
provided the values involved are endorsed by the decision-makers. 
The orthodox economic concepts of Pareto efficiency and opti-
mality, while endowed with a precise technical meaning, have 
little practical usefulness for economists who wish to inform the 
decision-making process in the real world [16,29,36,41]. While indi-
vidual utility is a relevant argument for inclusion in the social 
welfare function, it needs to be supplemented by information 
on other issues of concern to society, such as need, health status, 
equity and procedural justice [41–47]. Healthism also provides 
a well-developed theoretical framework that has been widely 
applied by health economists, but can be criticized for its neglect 
of societal values other than maximizing health status.
Rejection of the welfarist approach and limitations of the extra-
welfarist approach focus attention on the DMA as the theoretical 
framework that potentially enables most concerns to be addressed 
[29]. While intuitively appealing, it must be acknowledged that 
this framework has been subject to limited intellectual develop-
ment and debate. The challenge for normative economics is to 
develop an evaluative framework with enough rigor to be theoreti-
cally meaningful, but with enough flexibility to accommodate the 
range of complex elements that are relevant to evaluations of soci-
etal welfare. Economists working under the DMA framework are 
able to select from the full range of applied economic techniques 
(whether they are linked to welfarist or nonwelfarist foundations) 
restricted only by the relevance of the techniques to the research 
question. The DMA framework also allows analysts to go beyond 
the limitations shared by welfarism and extrawelfarism, provided 
the values involved are endorsed by the decision-makers. 
The choice of economic evaluation technique
The various economic evaluation techniques available either derive 
from, or can be related to, the three normative frameworks dis-
cussed. Each normative framework implies important differences in 
the specification of the economic protocol, including the delineation 
of the study perspective, the choice of comparators and the selection 
of evaluation technique. But there are also important similarities 
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between any evaluation methods that purport to be classified 
within the economics discipline. The concepts of ‘opportunity 
cost’ (Criterion Three), ‘marginal ana lysis’ (Criterion Four) and a 
‘clear concept of benefit’ (Criterion Two) are central to an economic 
approach to evaluation and priority setting [29,34,35]. Similarly, at a 
more applied level, rigor in the measurement of costs and benefits 
(Criterion Nine), together with the use of methods such as sen-
sitivity ana lysis, are characteristics of a quality study, rather than 
reflections of the underlying normative frameworks [34,35].
There would be debate, however, concerning what the com-
ponents of ‘benefit’ should be and how that benefit should be 
valued and aggregated. An important element of this debate 
involves distinguishing the question of how best to allocate 
resources across quite different programs (allocative efficiency) 
from the question of how best to pursue a chosen objective 
(technical and/or productive efficiency). Three key techniques 
form the foundation of economic evaluation: cost–benefit ana-
lysis (CBA), cost–utility ana lysis (CUA) and cost–effectiveness 
Box 1. Priority setting model checklist.
Criterion 1: is there a well-defined research question? (T, P, U)
Does the model specify a well-defined research question in answerable form? Is the model adaptable to variations in decision context • 
and setting? If not, are the general settings and purposes for which the model is appropriate specified? Is the model appropriate to the 
specific research question of the decision-maker(s) and the context in which it occurs? 
Criterion 2: is there a clear concept of benefit? (T, E, U)
Does the model have a mechanism or process to define benefit in a way that captures the perspective and objectives of the decision-• 
maker? Does the model establish a clear, logical connection between the concept of benefit, the research question and the priority 
setting objectives? Are the ethical values underlying the concept of benefit made explicit?
Criterion 3: is there an acceptable process for generating the options for change? (T, P, U)
Does the model have an explicit mechanism for generating options for change? Do the options generated pay specific regard to the • 
choice problem of the decision-maker(s) and the legitimate interests of stakeholders? Do the options for change meet the following 
criteria: comprehensiveness (important alternatives are not omitted; inclusion of both increments and decrements); relevance (to choice 
problem and decision-maker needs); evidence-based (including a process for establishing and dealing with the evidence base of options 
for change); defined in concrete terms so that the pathway of activities can be clearly determined; and manageable (the evaluation task 
is tractable in the time available)? 
Criterion 4: is marginal analysis an integral component? (T) 
Does the model utilize incremental ana lysis in comparing the options for change? Does it operationalize the measurement and ana lysis • 
of costs and benefits associated with the options for change through marginal ana lysis? Does the marginal ana lysis cover the scale and 
scope of the interventions, the target/user groups or mode of service delivery?
Criterion 5: are the decision rules clearly specified? (T, E)
Does the model clearly articulate the decision rules by which the options for change are ranked (e.g., maximization through equating • 
marginal cost and marginal benefit; maximization with equity weights; maximization subject to constraints; two-staged decision 
process)? Does the model specify how any multiple dimensions of benefit are weighted and aggregated? If outcomes are weighted for 
equity, are the equity principles, data sources and methods clearly specified?
Criterion 6: is the role of judgment recognized? (E, P, U)
Does the model check the need for judgment in the specification, application and interpretation of the technical ana lysis, particularly in • 
relation to underlying assumptions and values? Does the model make explicit the basis on which judgment impacts on the technical results? 
Criterion 7: are the data needs tractable? (P, U)
Does the model have a mechanism for making the data needs of the evaluation process tractable? • 
Criterion 8: is the need for due process recognized? (T, E, P, U)
Does the model check the need to place the technical ana lysis within a process for decision-making that contributes to the legitimacy • 
of the decisions and their acceptability to stakeholders? Is this process characterized by transparency and openness, accountability, 
fairness and reasonableness (unbiased; consideration given to all relevant factors; disregarding of irrelevant factors; accessing of 
relevant information); involvement of key stakeholders; consistency in decision-making; an appeal or review mechanism?
Criterion 9: do the measurement methods demonstrate appropriate rigor? (T, E, P, U)
Does the model involve a clearly specified evaluation protocol and standardized evaluation methods appropriate to the research • 
question? Does the measurement of costs and benefits strike a reasonable balance between expense, difficulty and timeliness? Is there 
sensitivity ana lysis of key design parameters and evaluation assumptions? Is there rigor in the implementation of both efficiency and 
equity objectives; recognition that the choice of outcome measures has important ethical implications?
Criterion 10: reporting/implementation (E, P, U)
Does the reporting address issues of likely concern to decision-makers, including ethical implications, feasibility of implementation, • 
acceptability to stakeholders, importance of the problem addressed and financial implications? Is the reporting format designed to assist 
with judgments on what weight might be placed on the results, including generalizability to other settings and contexts, consultation 
processes adopted, strengths and weaknesses of the technical ana lysis, including comparison with similar evaluation studies in the literature? 
For each criterion the letters in parenthesis indicate the relevant rationale: economic theory (T), ethical rationale (E), pragmatic rationale (P) and user 
considerations (U). 
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ana lysis (CEA). Program Budgeting and Marginal Analysis 
(PBMA) is also significant [4], but more from a priority setting 
perspective, than from an evaluation techniques perspective. 
This judgment reflects PBMA’s role in providing an appropri-
ate decision-making process, as well as its ability to incorporate 
various techniques for assessing value (such as CBA, CUA and 
CBA or options appraisal). 
Orthodox welfarists see CBA as the gold standard of economic 
evaluation, because in principle, with both costs and benefits mea-
sured in dollar terms, CBA can determine whether a particular 
project is ‘worthwhile’. Both CEA and CUA were embraced by 
extrawelfarists because of the difficulties (conceptual, ethical and 
practical) in placing a dollar value on life. Costs are still measured 
in dollar terms, but outcomes are measured in either natural units 
of outcome for the programs being evaluated (for CEA) or quality-
adjusted life years (QALYs); (for CUA). CEA can be quite powerful 
where the policy question is how best to provide a given interven-
tion (technical efficiency), but the lack of a common metric that 
picks up both mortality and morbidity impacts limits its role in 
allocative efficiency. CUA lies somewhere between CEA and CBA 
in terms of the problems it can address, but exactly where is an issue 
of some debate [29]. It can be seen as either a form of CEA that can 
cope with more than one form of output (combining quantity of 
life and quality of life); or as a form of CBA where QALYs are the 
criteria of value (rather than dollars) and where rankings can be 
made for setting priorities within a fixed health sector budget.
While there are certainly important conceptual and practical 
questions associated with CUA, the technique is our preferred 
evaluation technique for the health sector. Final selection of tech-
nique, however, cannot be divorced from the decision context. If 
health-related quality of life is of small importance for the inter-
ventions in a particular decision context, then CEA may well be 
a more efficient use of research dollars.
Rationale two: lessons from the literature on social justice 
& ethics
Moral reasoning, like economics, involves the use of logical argu-
ment whereby decisions and their rationale are made explicit. 
Ethicists are likely to be divided, however, on the importance of 
empirical evidence in agreeing values and societal objectives. Most 
would accept the proposition that the starting point for judgments 
about whether society is better or worse off is a framework of 
normative ana lysis that is congruent with the fundamental values 
that prevail in that society. On the other hand, some would stress 
the role of moral reasoning as opposed to community prefer-
ences [25–27]. Richardson’s view [41,42] that these normative values 
Box 2. Key findings from the four rationales on which the checklist is based.
Conclusions on economic theory:
The Decision-Making School (DMA) is our preferred normative foundation, although it is less developed than orthodox welfarism or • 
extra-welfarism.
Cost Utility Analysis (CUA) is the preferred technique of economic appraisal, however, final selection of technique cannot be divorced • 
from the decision context.
Lessons from literature on ethics and social justice:
Ethical reasoning supports an explicit approach to priority setting (underlies a number of criteria, particularly Criterion 10: reporting).• 
Ethical reasoning offers no decision rules to choose between conflicting ethical theories or principles. (Criterion 2: concept of benefit; • 
Criterion 6: role of judgment and Criterion 8: due process).
There is no logical way of resolving divergent ethical views other than through structured discussion and recognition of the legitimacy • 
of alternative viewpoints. (Criterion 8: due process).
While the various equity concepts are useful to decide when a ‘need’ exists, they are less useful in deciding how much healthcare is • 
required to meet that need. This provides for a natural coalition between needs-based concepts of equity and the efficiency principle in 
assisting policy decisions.
Lessons from empirical experience with priority setting:
Priority setting needs to combine technical methodologies, such as economic evaluation, with a concern for ‘due process’ for decisions • 
to have legitimacy across multiple stakeholders (Criterion 8t: due process).
Economic evaluation may produce results that are unexpected and/or unacceptable to some, particularly if the program objectives and • 
the concept of benefit are not clearly discussed in advance (Criterion 2: concept of benefit).
Economic evaluation has been regarded as useful and fundamental to the priority setting process, but within a restricted role • 
(Criterion 1: the research question).
The empirical experience raises important issues about what constitutes ‘adequate’ data and how the data requirements of technical • 
approaches can be made tractable (Criterion 7: data needs).
Ultimately, priority setting rests on judgment informed by evidence (Criterion 6: role of judgement).• 
Needs of decision-makers:
Specifying a core set of services to be funded has proven difficult (Criterion 1: the research question).• 
Developing guidelines (rather than service exclusion) has attracted widespread support (Criterion 1: the research question).• 
The importance of a strategic approach to deal with the inherent complexity and ongoing nature of priority setting (associated policy/• 
infrastructure issue). 
Priority setting has important management and organizational dimensions (Relevant to criteria 1, 3 and 6–10).• 
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need to be established through what he calls ‘empirical ethics’, 
the intermingling of empirical evidence on what the community 
values and ethical debate, is a sensible way to precede, particularly 
if combined with a concern for procedural justice. 
It is important to recognize that while ethical reasoning involves 
a rational approach to problem ana lysis, it offers no decision rules 
to choose between alternative ethical approaches. Deontology 
and consequentialism, together with distributive justice, stand 
out amongst the ethical issues of relevance to priority setting in 
healthcare [29]. Deontology focuses on duty, process and the rights 
of the individual; consequentialism focuses on outcomes and the 
collective good of society; while distributive justice involves the 
idea of balancing the competing claims of individuals in a way that 
is seen as impartial and fair. Most stakeholders in priority setting 
activities will hold views that reflect a combination of these ide-
ologies, with the particular combination likely to vary with their 
background and experience, together with the choice problem 
and setting. There is no logical way of resolving divergent ethical 
views other than a convergence of thinking through structured 
discussion and recognition of the legitimacy of alternative view-
points. In our ACE methods, therefore, specific provision is made 
for stakeholder involvement, with deliberative discussion based on 
best available information and consensus decision-making.
There is widespread agreement about the importance of dis-
tributive equity, but this does not translate easily into agreement 
about what the relevant concept of equity should be. Concepts of 
equity that have received the most sustained attention are: 
Allocation according to need•	
Allocation according to health status•	
Allocation to ensure equality of health access•	
The principle that healthcare resources should be prioritized 
according to need has strong intuitive appeal and, for this reason, 
‘need’ is a popular approach used both on its own and in combi-
nation with the health status and access definitions. To be of prac-
tical use, however, the concept of need has to be defined clearly, 
with at least three definitions existing in the literature. These 
range from need defined as extent of illness or size of the problem 
(based on epidemiological data and/or community surveys), by 
disease severity and by the existence of an effective intervention 
(often combined with capacity-to-benefit). Under the principle 
of allocation according to need, horizontal and vertical equity 
call for equal treatment for equal need (‘horizontal equity’) and 
unequal (but fair) treatment in proportion to unequal need (‘ver-
tical equity’). While these various concepts are useful to decide 
when a need exists, they are less useful in deciding how much 
healthcare is required to meet that need [6]. 
Given that healthcare is mostly consumed for instrumental rea-
sons, that is, to promote good health, there is a strong argument to 
consider equity in terms of health status. In policy terms, this equity 
principle is often expressed as minimizing inequalities in health 
status. The question of differential aggregation weights to imple-
ment this equity principle has received considerable attention in 
the literature, particularly in the context of weights to adjust health 
outcomes in economic evaluation. To the extent that distributive 
concerns can be linked to the characteristics of people (such as age, 
ethnicity/Aboriginality, rurality/remoteness and socioeconomic 
status), a system of weights may be able to reflect these concerns. An 
important issue in designing weights is the appropriate source and 
rationale for the equity principle(s) involved. In this regard, equity 
weights can be developed based on community preferences and/or 
reflect an equity principle selected by the researcher/decision-maker 
based on moral reasoning. Recent work based on community pref-
erences has focused on illness severity and health potentials, while 
the ‘fair innings’ approach is a good example of weights based on 
both moral reasoning and empirical evidence [27,44].
The third major approach to distributive equity is allocation to 
achieve equality of access. The ethical basis is one of ensuring a 
‘fair chance’ and is commonly found in policy statements in the 
form ‘equal access for equal need’. While there are certainly issues 
in defining access the principle carries strong egalitarian overtones 
and enjoys strong empirical support [29]. The choice of equity con-
cept is critical, because achieving equality in respect of one equity 
dimension usually means accepting inequality in regard to other 
dimensions. There is no ‘scientific’ basis for choosing between rival 
notions of equity as normative principles. Judgment is required hav-
ing regard to policy objectives, decision context, community values 
and the theories of social justice held to be the most appropriate. It 
is important to note that the three approaches to distributive justice 
outlined will generally lead to different answers for the allocation 
of resources. Nowhere is this more apparent, for example, than 
in the ‘fair chances versus best health outcomes’ trade-off. When 
general principles of distributive justice fail to provide clear-cut 
answers, then the focus of social justice shifts to the legitimacy 
provided by a just process for making decisions. The issue of legiti-
macy of priority setting decisions in the eyes of stakeholders leads 
on to what has worked in practice and to the pragmatic concerns 
of decision-makers.
Rationale three: lessons from empirical experience
The experience of Oregon in the USA, The Netherlands, New 
Zealand, Sweden, Israel and the Nordic countries over the last 
decade or so exemplify the emergence of explicit priority setting 
as a national initiative [1,7,29]. In each of these countries priority 
setting entered the national health policy agenda as the scope of 
publicly financed health services came under review. In Australia 
and the UK there have been no similar systematic efforts to estab-
lish a national framework in which explicit criteria are clearly laid 
out, with ethical values established through community consul-
tation. There are, nonetheless, relevant empirical experiences in 
priority setting from which lessons can be drawn [17–19,48–50].
The empirical evidence available suggests that while the vari-
ous technical approaches have undoubtedly made an important 
contribution, no country has adopted a purely technical approach. 
The role of economic evaluation in the countries reviewed has 
reflected the significance afforded efficiency as an objective of 
their healthcare systems, together with difficulties encountered 
in the practical application of economic evaluation techniques. 
All countries reviewed, including Sweden, embraced efficiency 
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as an important objective, but clearly not the only objective, and 
often not the most important objective. For most countries, the 
importance placed on different objectives reflected their underly-
ing ethical values (e.g., effectiveness, solidarity/fairness, severity 
and efficiency). All countries have come to recognize that if their 
decisions were to have legitimacy for patients, providers and the 
general public, then a balance had to be struck between tech-
niques and decision rules drawn from disciplines like economics, 
and a concern for due process and consultation [1,7,29]. 
In relation to evaluation techniques, most countries recognized 
that the broader the priority setting task attempted, the more 
likely economic evaluation would encounter technical problems. 
Several countries (New Zealand and the Nordic countries) pre-
ferred to focus economic evaluation on vertical priority setting 
(on interventions for dealing with the same disease or problem) 
and/or within the context of guidelines or dealing with new 
technologies. The Australian experience is similar. The use of 
economic evaluation within a restricted role, such as assisting 
the decisions of the Australian Pharmaceutical Benefits Advisory 
Committee (PBAC) or the Medical Services Advisory Committee 
(MSAC), has been well regarded. Experienced evaluators have 
questioned the suitability of available economic evaluation tech-
niques in application to entire domains of healthcare. Those 
initiatives that have sought a much broader application (such as 
Oregon [7], the Health Benefits Group/Health Resource Group 
approach [30], and the Health Sector Wide Disease Model [31]), 
have encountered significant data problems that have limited 
their usefulness [29]. These approaches have sought to make the 
task more tractable by either limiting the scope of the research 
question, restricting the role of economic evaluation, or by with-
drawing from priority setting to a more general planning and 
scenario assessment role. Techniques such as PBMA that provide 
a structure in which evidence and values can be brought together 
are growing in popularity [4,48–50]. In Australia, the early appeal 
of the consensus-based approaches reflected their focus on due 
process, particularly the effective involvement of participants in 
the decision-making process [20–22]. 
Finally, priority setting is not just about making one set of deci-
sions, but recognizing ‘the complex interaction of multiple decisions, 
taken at various levels’ [51,52]. In New Zealand, for example, it is 
not clear whether recommendations coming out of their guidelines 
development process will match up with the purchasing recom-
mendations that come from their PBMA process [53]. In the UK, 
NICE has been criticized for not taking into account the cost of its 
recommendations on regional bodies that are meant to implement 
them. There are concerns that NICE recommendations will distort 
efforts to establish priorities at the local level [54]. The empirical evi-
dence thus highlights the reality that explicit rationing at all levels 
involves both the use of techniques and the application of judgment. 
The empirical experience also confirms that there are no simple 
solutions to the challenges posed by the need for priority setting. 
Complexity is inherent in the range of stakeholders involved, the 
various levels at which decisions are taken, the need for both verti-
cal and horizontal priority setting and the importance attached to 
ethical values and principles. 
Rationale four: user considerations
Criteria with a user rationale stem from an effort to ensure that mod-
els of priority setting respond to the particular needs of healthcare 
decision-makers. Attempts to make priority setting more explicit 
have also revealed the difficulty of defining a basic package of ser-
vices by excluding some treatments from public funding. Quite apart 
from the empirical evidence, the ‘exclusion’ approach is inconsistent 
with the importance placed on marginal ana lysis in finding ‘effi-
cient’ solutions in economic theory. Reliance on average cost–effec-
tiveness results ignores the variation in cost–effectiveness ratios with 
patient needs, population sub-groups, program size, program design 
and health service setting. There are few treatments that are wholly 
effective or wholly ineffective and the challenge is to ensure that the 
services that are funded are provided to those patients who stand 
to benefit. For both sound practical and theoretical reasons, those 
charged with the responsibility for rationing have usually declined 
to use the exclusion approach. The experience to date suggests that 
where exclusions have been achieved they have tended to be inter-
ventions involving minor ailments and/or interventions for which 
the evidence was lacking. They are all marginal to mainstream 
medicine. While not preparing detailed lists of the type adopted in 
Oregon, several countries have adopted health service classification 
systems based on illness severity/perceived importance, that have 
proven to be useful (Sweden, Norway, Finland and Denmark) [29].
The natural consequence of the difficulties inherent in ration-
ing by exclusion is the increasing interest being shown in setting 
priorities by drawing up guidelines for the provision of services. 
The focus has changed from which services or types of care should 
be provided, to which patients should be selected for what kinds 
of treatment and at what level of intensity. The focus on rationing 
by guidelines also reflects the wider movement to strengthen the 
scientific basis of medicine and the associated concern to reduce 
variations in clinical practice patterns. 
How do existing approaches perform against 
the checklist?
Noneconomic approaches
Surveys across a number of countries suggest that probably the most 
common approach to resource allocation in health is to base fund-
ing decisions on what has been funded in previous years [4]. This 
historical allocation approach can be made a little more rigorous 
by pro rating allocations up or down based on changes in health 
service costs and/or demographic changes. As a lack of explicit 
priority setting activity is characteristic of this type of approach, it 
is common for local politics to enter into the process. Mitton calls 
this latter mechanism the ‘decibel approach’ [4]. While common-
place, this approach fails most of the checklist; particularly a clear 
concept of benefit, a process for generating options for change, clear 
decision rules and marginal ana lysis. Importantly, neither history 
nor decibels provide a mechanism for maximizing policy objectives 
(including health gain) within a given budget. Interestingly, while 
the simplest to administer, there is growing evidence that managers 
and clinicians find little satisfaction with approaches where implicit 
values and politics dominate, rather than evidence of effectiveness, 
sound judgment and explicit decision-making processes [4]. It is no 
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surprise that the priority setting literature is dominated by discus-
sion of the relative merits of explicit verses implicit approaches and 
of how explicitness should be achieved [5,7,17,18].
Another commonly used means of setting priorities is through the 
assessment of ‘need’ employing various epidemiological techniques. 
One approach to needs assessment is to define need either at the 
individual or population level, and then set a minimum standard 
of care (or set of services) to meet that need. Needs assessment, for 
example, was given a pivotal role in the development of purchasing 
in the National Health Service internal market reforms of the early 
1990s in the UK and is utilized by many public health units in 
various states of Australia [29]. Need, however, as discussed earlier, 
is a complex concept, with many different definitions provided in 
the literature. The crucial distinction is between defining need as 
the extent and/or severity of illness (‘health needs’) and defining 
need as the capacity-to-benefit (‘healthcare needs’). Early enthusi-
asm for needs assessment by purchasers in the UK and elsewhere 
waned, largely because of its limited relevance for specific purchas-
ing decisions, coupled with the size of the research task. Without 
intervention-specific cost data and the decision rules offered by 
economic appraisal, there are formidable difficulties in trying to 
set priorities from needs data. This poor performance is reflected 
in failure to meet key criteria from the checklist – particularly 
marginal ana lysis, decision rules and data tractability (Box 3). 
Even when there have been attempts to explicitly link needs 
assessment with expenditure, such as with resource allocation 
formulae (RAF),  such formulae have been helpful with the 
equitable distribution of regional budgets, but have not assisted 
specific purchasing decisions. This reflects their lack of atten-
tion to option generation/selection, the absence of decision rules 
Box 3. Needs-based models of priority setting.
Criterion 1: Well-defined research question. Adaptable to decision context and setting
Clarity in research question varies between methods and from study to study. Some models take a broad-based societal perspective • 
(such as the WHO global burden of disease study [GBD] and associated national disability-adjusted life-year [DALY] or ‘avoidable 
mortality/morbidity’ studies), while others focus on specific diseases and particular health service sectors. Well-defined research 
question is achievable within context of clear model objectives.
Criterion 2: Clear concept of benefit
Few of the needs-based approaches explicitly consider priority setting objectives and what these mean for the concept of benefit. • 
Equity is a complex concept and few studies define it clearly. Needs-based models do not have an in-built mechanism to discuss and 
clarify concept of benefit with stakeholders. Most assume disease/health is the distribuendum. Broader objectives are rarely canvassed, 
although their descriptive nature does allow equity issues to be explored.
Criterion 3: Process for generating options for change
‘Health needs’ studies focus on a description of the size and distribution of disease problem, rather than health gain or interventions. • 
‘Healthcare needs’ studies take into account whether efficacious interventions exist, but rarely provide advice on option generation/
selection matched to specific decision contexts.
Criterion 4: Marginal analysis
Needs-based models are not based on economic principles and do not involve marginal ana lysis or opportunity cost principles.• 
Criteron 5: Clear decision rules
Fail to incorporate decision rules for priority setting in a situation of resource scarcity. Needs-based models generally contain no • 
mechanism to adjust health service mix towards the optimal (such as the ‘marginal benefit = marginal cost’ rule of economics).
Criterion 6: Role of judgment noted and clearly specified
Performance would vary between models and studies. The better studies would make explicit the role of judgment in specification, • 
application and interpretation of the technical ana lysis.
Criterion 7: Data needs made tractable
Like most forms of technical priority setting, needs-based approaches can involve large requirements for data that often pose • 
considerable problems. Existence of the requisite data on disease incidence/prevalence, duration, mortality and disease burden varies by 
disease and from country to country. Integration of quality of life weights involves further detailed data and ethical issues. Modeling 
and simplifying assumptions are often employed.
Criterion 8: Due process
Needs-based models, like most technical approaches, rarely give consideration to issues of procedural justice. Most studies endeavor to • 
make their methods explicit. Involvement of stakeholders varies between models.
Criterion 9: Rigorous approach to measurement
Performance varies from study to study. A rigorous and balanced approach to measurement is achievable.• 
Criterion 10: Reporting issues of concern to decision-makers
Some issues of concern to decision-makers not covered by approach (financial cost; allocative and technical efficiency). Coverage of • 
other issues (e.g., ethical values, feasibility and acceptability to stakeholders) would vary from study to study.
Overall assessment
Needs-based models have been useful in distributing regional budgets (Resource allocation formula), in prioritizing problems, and in • 
estimating potential benefits. Failure to provide mechanism to address choice between different needs/interventions compromises 
ability to guide individual purchasing decisions. Best utilized to provide need/severity classification systems and as an input to decision-
making where decision rules are introduced from efficiency-based models.
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to guide purchasing and reliance on burden of disease data (as 
opposed to information on the costs and benefits of specific inter-
ventions). All this is not to say that needs assessments are not 
important or that descriptive data sets on the burden of disease 
or cost of illness cannot be helpful as an input to priority setting. 
Such data can be useful in identifying unmeet need, in flagging 
societal inequalities and when linked to economic evaluation, in 
assessing cost offsets and potential health gains. However, needs 
assessments alone are not useful for promoting the efficient use 
of resources and are not best used as a primary mechanism for 
setting priorities.
Interesting endeavors at explicit consensus-based approaches 
to priority setting have also been conducted in Australia [20–22]. 
The ACE case study presented later resulted from perceived 
def iciencies of one important example of the consensus 
approach, involving the development of a national cancer strat-
egy in Australia. Another interesting example in Australia [20] 
involved the development of priority areas for health promo-
tion for women in the Hunter region of New South Wales. 
In this approach epidemiological data on disease incidence 
and distribution, views from the community and advice from 
experts were synthesized using a nominal group approach. This 
consensus model clearly had advantages in terms of its poten-
tial to achieve legitimacy in the eyes of stakeholders. There 
were also, however, some important weaknesses that compro-
mised its potential to guide resource allocation decisions. These 
related principally to the type of information provided (e.g., no 
resource cost information), the omission of economic appraisal, 
the lack of precision in how criteria were to be used for ranking 
options and the primary focus on the size of the problem rather 
than on health gain (Box 4).
Carter reviewed a wide range of noneconomic models and con-
cluded that while several had innovative aspects and demonstrated 
merit in relation to some of the criteria on the checklist, none per-
formed well against all of the criteria [29]. All the models proposed 
by noneconomists had serious weaknesses that compromised their 
credentials as stand-alone guides to resource allocation, particu-
larly as guides to purchasing decisions. They are best utilized in 
combination with an economic approach that provides guidance 
on efficiency.
Box 4. The ‘three-stage consensus model’ of priority setting.
Criterion 1: Well-defined research question. Adaptable to decision context and setting
Applications illustrate this is achievable with the ‘three-stage model’. Note, however, that the potential of this model to apply to • 
purchasing decisions (as opposed to selecting targets or work programs) has not yet been demonstrated.
Criterion 2: Clear concept of benefit
The approach to date has focused more on prioritizing the problem, rather than prioritizing interventions. There is a lack of precision at • 
present in defining criteria and their relative weight in the voting process.
Criterion 3: Process for generating options for change
Selected by research team in response to problems/targets prioritized by the Working Party. Mechanism and criteria for selection of • 
options not specified. While ‘opportunity cost’ implicit in voting process, compromised in option selection process.
Criterion 4: Marginal analysis
Not utilized.• 
Criterion 5: Clear decision rules
Rules of nominal group and voting process are clearly specified. Relationship between selection criteria and vote not made explicit. • 
Links between vote and purchasing implications not clear (no budget information provided, no cost data provided, no apparent 
decision rule to guide purchasing decisions).
Criterion 6: Role of judgment
Clearly specified in relation to voting process and nominal group approach. Model well positioned to achieve consensus for opinion-• 
based judgments, although clarity in use of decision criteria could be improved.
Criterion 7: Data needs made tractable
Working Party assisted by research team. Data process places reliance on readily available epidemiological data and key informant • 
judgments. Efficacy and efficiency data based on literature review. Only community survey involves substantial data collection issue.
Criterion 8: Due process
Major strength of this model. Demonstrated effective capacity to satisfy concerns of ‘due process’. Stakeholder participation and • 
effective involvement encouraged by nominal group approach.
Criterion 9: Rigorous approach to measurement
Acceptable in some aspects, but very questionable on others (such as efficacy data on interventions, economic evidence on • 
interventions and lack of precision in decision rules).
Criterion 10: Reporting issues of concern to decision-makers
Achievable within research question adopted. Reflects strength in achieving consensus. Note weaknesses in efficacy and efficiency may • 
impact here.
Overall assessment
Offers important strengths in achieving consensus and effective stakeholder participation. Role in assisting purchasing not • 
substantiated at this time. Best utilized in combination with an economic approach, if intended as a model of priority setting to aid 
purchasing decisions (as opposed to selecting targets or prioritizing problems).
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Economic approaches
There are a number of economic approaches to priority setting. 
Two common approaches are selected here to illustrate the defi-
ciencies of current approaches, the use of league tables (Box 5), and 
program budgeting and marginal analysis (Box 6). 
In recent years it has become common practice for the results 
of economic evaluations to be brought together to provide a 
‘league table’, in which the interventions are ranked in order 
of their cost per life year or cost per QALY results. While this 
approach has intrinsic appeal, economists have urged caution in 
using league tables to set priorities for three key reasons. First, for 
the information in league tables to be of use to decision-makers, 
they need to be confident that the methodology of the source 
studies is sound and that it is relatively homogeneous across the 
various studies. The aim is to ensure that the economic merit of 
the interventions evaluated is not confounded by differences in 
evaluation approach and associated assumptions. Second, those 
league tables compiled from a review of the literature often 
include studies from a range of settings and the economic and 
epidemiological data may not be easily transferable from one 
setting to another. Third, there are issues associated with the 
practical application of decision rules in the presence of indivis-
ibilities and a budget constraint which warrant caution against 
simplistic interpretation [29,34,35].
Box 5. League table model of priority setting.
Criterion 1. Well-defined research question. Adaptable to decision context and setting
Clarity in research question, together with scope, perspective and context varies from table to table. League tables are adaptable to • 
problem setting and context, and are sometimes incorporated into other broad-based approaches to priority setting (such as PBMA). 
Well-designed research question is potentially achievable with league table approach to priority setting.
Criterion 2. Clear concept of benefit
Few league tables explicitly consider priority setting objectives and what this means for the concept of benefit. Most league tables • 
simply assume a ‘health gain’ definition of benefit, with no attention to broader issues such as distributive equity or procedural justice.
Criterion 3. Process for generating options for change
There is no in-built mechanism in league tables for option generation and selection. Selection process varies from analyst discretion • 
(literature review based league table) to dictates of problem context (PBAC league table). Rationale for option selection is rarely 
well-documented.
Criterion 4. Marginal analysis
Most league tables report average CEA/CUA results, rather than marginal ana lysis. Decisions based on averages, especially when • 
condition/treatment pairs involve disparate patient groups, are unlikely to maximize community benefit. This is more a criticism of 
current practice than intrinsic to method.
Criterion 5. Clear decision rules
Incorporates decision rules for priority setting in situation of resource scarcity. Not decisive in absence of budget constraint, without • 
pre-defined shadow price (such as $50,000 per QALY). Opinion varies about appropriateness and practicality of using shadow price of 
societal willingness-to-pay for health gains.
Criterion 6. Role of judgment noted and clearly specified
Performance varies between tables. The better studies would make explicit the role of judgment in specification, application and • 
interpretation of the technical ana lysis. Many league tables have substantive implicit elements, as evidenced by PBAC and Oregon. 
Ethical issues are rarely made explicit.
Criterion 7. Data needs made tractable
Many league tables simply rely on reviewing the economic literature as the source of studies. There is no other mechanism to make data • 
needs tractable, unless league table is incorporated into broader approach where such mechanisms exist (such as MEEM).
Criterion 8. Due process
There is no consideration of ‘due process’ or discussion mechanism inherent in the league table approach, unless it is combined with a • 
broader approach to priority setting.
Criterion 9. Rigorous approach to measurement
Performance varies from table to table. League tables based on a literature review would be susceptible to confounding due to variation • 
in methods and setting of source studies. Rigorous and balanced approach to measurement is potentially achievable, however, 
particularly if appraisal is part of the priority setting approach. This in turn raises issue of data tractability.
Criterion 10. Reporting issues of concern to decision-makers
Some issues of concern to decision-makers not covered by basic league table approach, unless part of broader approach (financial cost; • 
distributive equity; feasibility; acceptability to stakeholders).
Overall assessment
League tables need to be handled with caution, both in terms of their technical validity and the weight placed on ratios based on a • 
narrow interpretation of benefit and implicit value judgments. League tables are more likely to make a positive contribution if utilized 
within a broader approach to priority setting that involves distributive equity, procedural justice and a macro economic evaluation 
protocol specifically designed for a multiple intervention decision context.
CEA: Cost–effectiveness ana lysis; CUA: Cost–utility ana lysis; MEEM: Macro Economic Evaluation Model; PBAC: Pharmaceutical Benefits Advisory Committee;  
PBMA: Program Budgeting and Marginal Analysis; QALY: Quality-adjusted life year.
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Box 6. Program budgeting and marginal analysis model of priority setting.
Criterion 1. Well-defined research question. Adaptable to decision context and setting
Most PBMA studies have been undertaken at a regional or organizational level, but studies at the national level are also feasible. The • 
horizontal/vertical design options for PBMA provide flexibility for adaptation to various decision contexts and settings; although 
horizontal (or macro) studies have proven difficult to achieve in practice. PBMA can be undertaken as one-off study or institutionalized 
as ongoing planning process. Study perspective will vary between applications in accordance with context and setting.
Criterion 2. Clear concept of benefit
Achieving a clear concept of benefit is a major strength of the PBMA approach, with clarification of objectives a basic step in the PBMA • 
process. The Working Party provides the vehicle for discussion and clarification of the concept of benefit and underlying values with 
stakeholders. Broader objectives can be canvassed, and integrated using decision theory, options appraisal or a two-staged approach.
Criterion 3. Process for generating options for change
Discussion of option generation/selection is an important matter for the Working Party to discuss and decide. A more formalized • 
process, involving a research team assisting the Working Party, is an important way of improving the comprehensiveness and rigor of 
the option selection process and controlling ‘gaming’ or domination of Working Party discussion. PBMA can be undertaken as an 
iterative and ongoing process to increase coverage of current activities and options for change.
Criterion 4. Marginal analysis
PBMA is based on the fundamental economic principles of marginal ana lysis, opportunity cost and clear concept of benefit. The level to • 
which marginal ana lysis is achieved will vary from study to study. Simplifying assumptions (e.g., that equate average and marginal 
changes for subgroups) are not uncommon, but this is true for most applied economic evaluation work. PBMA can embody the full 
range of economic evaluation techniques.
Criterion 5. Clear decision rules
PBMA applies standard optimization rules of economics, although they may be subject to adjustment to reflect broader objectives. • 
Particular rules will depend on evaluation technique utilized (CEA, CUA, CBA, options appraisal). Any modification of standard decision 
rules should be clearly specified.
Criterion 6. Role of judgment noted and clearly specified
Performance on this criterion would vary between studies. The better studies would make explicit the role of judgment in specification, • 
application and interpretation of the technical ana lysis and any broader issues taken into consideration. Scope exists for the clarification 
of ethical values in Working Party discussion, but such discussion would not be commonplace at present.
Criterion 7. Data needs made tractable
Data needs are made tractable at present through undue reliance on opinions of Working Party, but this practice may compromise validity of • 
conclusions and confidence in PBMA approach. Undertaking an evidence-based approach will require research support for Working Party 
and may require linking PBMA with other approaches (such as MEEM) that incorporate a macroevaluation protocol and in-built mechanism 
for resolving data needs. Institutionalizing PBMA at organizational level will require linkage with existing financial and statistical collections.
Criterion 8. Due process
PBMA provides a mechanism, through the Working Party, to give consideration to issues of procedural justice. Most studies endeavor to • 
make their methods explicit. Nature and degree of involvement of stakeholders varies between studies.
Criterion 9. Rigorous approach to measurement
Has been a point of major criticism of early PBMA studies, which relied on judgment rather than evidence for assessing intervention • 
performance. Rigorous and balanced approach to measurement is potentially achievable, however, with PBMA approach.
Criterion 10. Reporting issues of concern to decision-makers
All issues of concern to decision-makers are potentially covered by PBMA approach, although performance would inevitably vary from • 
study to study. Evidence to date suggests that addressing organizational and managerial issues will be central to successful 
implementation.
Overall assessment
Capable of providing both a valid and practical approach to priority setting in many contexts. Criticisms reflect more ‘growing pains’ of • 
evolving technique than fatal flaws in underlying structure or rationale. Criticisms such as lack of measurement rigor, inadequacies in 
option selection, narrow perspective and poorly developed marginal ana lysis are all resolvable within PBMA approach, as evidenced by 
recent developments. Data tractability, however, will be a problem once the current reliance on expert opinion is removed to achieve a 
more rigorous methodology. Evidence to date suggests addressing data tractability, organizational and managerial issues will be central 
to successful implementation.
CBA: Cost–benefit ana lysis; CEA: Cost–effectiveness ana lysis; CUA: Cost–utility ana lysis; MEEM: Macro Economic Evaluation Model; PBMA: Program Budgeting and 
Marginal Analysis.
In addition to these technical concerns raised by economists, 
there are also concerns stemming from the social justice and 
empirical experience rationales reviewed earlier. It is clear that 
irrespective of technical merit, policy makers and the communi-
ties they represent do not wish to see automated decision-making 
based on cost–effectiveness ratios.
Program Budgeting and Marginal Analysis is an approach to 
priority setting specifically designed as a practical guide for deci-
sion-makers in the planning and provision of health services. The 
starting point for most PBMA studies has been to examine how 
resources are currently spent before focusing on incremental gains 
and costs of changes in current activities, through comparison 
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across or within programs. In practice the question of whether 
current resources are being used optimally is generally formulated 
in terms of how to allocate relatively small increases or decreases 
in expenditure of say 5–10% around the current level. 
It is clear from a growing literature on PBMA [4,29] that sub-
stantially different evaluation approaches have emerged within 
this overarching framework. While the steps in conducting a 
PBMA are broadly similar between studies, rigor in the selection 
of options, in the consultation/bargaining process, in the measure-
ment of costs and benefits, and in the level of evidence demanded, 
all vary substantially. Most attempts at PBMA have relied on local 
subjective judgments for assessing the effectiveness of options for 
change, and for some observers this, together with the possibility of 
‘gaming’ and/or reinforcement of the status quo, has undermined 
their credibility [55,59]. Other researchers, however, including the 
ACE team, have sought to improve the evidence base of PBMA 
[56–58] in line with the growing acceptance of the evidence-based 
medicine movement. 
In Box 6 we conclude that the PBMA technique is capable of pro-
viding a valid and practical approach to priority setting, but requires 
development. Many of the criticisms reflect more the ‘growing pains’ 
of an evolving technique, than fatal flaws in its underlying structure 
or rationale. Criticisms, such as lack of measurement rigor, inadequa-
cies in option selection, narrow perspective and poorly developed 
marginal ana lysis [55,59], are all resolvable as evidenced by the ACE 
work, which sits arguably within the PBMA genre. 
Description of the ACE model & its unique features 
The ‘ACE’ approach, summarized in Figures 1 & 2, reflects our endeav-
ors to develop an approach that satisfies the checklist, particularly 
the challenge of finding an appropriate balance between technical 
rigor and due process. We tested and refined this balance through 
a series of case studies that are summarized in TaBle 1. We are reas-
sured by the fact that the ACE approach has appealed to both our 
academic peers across a range of disciplines (reflected in competitive 
grants) and to decision-makers in government and provider orga-
nizations (reflected in commissioned work). The decision context 
for most ACE evaluations has been the possible adoption Australia-
wide of options to improve the efficiency of current health services 
and to inform policy makers about the best bundle of interventions, 
given alternative levels of budget availability.
On the technical side, the ACE approach applies the key economic 
concepts of ‘opportunity cost’, ‘marginal ana lysis’ and a ‘clear con-
cept of benefit’ using standardized evaluation methods clearly docu-
mented in an evaluation protocol. Undertaking the economic evalua-
tions as part of the priority setting exercise addresses the reservations 
expressed by many economists regarding the simplistic use of league 
tables, where economic studies are assembled from the literature with 
little regard to differences in methods, context and setting. The key 
characteristics of the ACE evaluation methods are: 
The rationale for the selection of interventions is discussed and •	
clearly specified;
The evaluation methods are standardized, documented and •	
open to scrutiny;
The CUA is used to develop incremental cost–effectiveness •	
ratios (ICERs) based on economic/epidemiological modeling 
techniques that utilize best-available data; 
The ICERs, total costs and disability-adjusted life years •	
(DALYs) are reported as a range (around point estimates) 
reflecting explicitly the uncertainty of cost, process, outcome 
and value estimates;
The setting, context and comparator are common to all •	
interventions;
Country-specific data are used, wherever possible, for health •	
system costs and demographic and epidemiological 
disease parameters;
Data needs are made tractable by utilizing Australian DALY •	
data as the primary measure of health outcomes (adjusted for 
application within an evaluation context) [60], together with the 
Australian Disease Costs and Impacts data (DCIS) to assist 
with cost offset estimates [61];
The ICERs are placed within a broader decision-making frame-•	
work that includes ‘equity’, ‘strength of evidence’, ‘feasibility of 
implementation’, ‘acceptability to stakeholders’ and other study-
specific considerations, which we have our called ‘second-stage 
filter’ ana lysis;  
Information is assembled by a multidisciplinary research team, pre-•	
paring briefing papers to a standardized format agreed by a Work-
ing Group of stakeholders who are involved throughout the study.
Research question
• Researcher initiated
• Decision-maker initiated 
Select interventions
• Agree selection criteria
• Apply to get agreed work program
Confirm evaluation methods
Technical analysis ($ cost per QoL measure
• Second-stage filters (e.g., equity, acceptability)
Undertake technical analysis and second-stage filter analysis
• Cost–efficacy to cost–effectiveness and acceptability
Agree findings and disseminate
Create Working Group of stakeholders
Figure 1. Overview of steps in the 
Assessing Cost–Effectiveness approach to priority setting. 
QoL: Quality of life.
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ACE Working Groups generally consist 
of stakeholders recruited from topic experts, 
clinicians and practitioners, relevant com-
munity organizations and policy makers. 
The Working Group in ACE studies has an 
important role in selecting the interventions 
for evaluation, as well as achieving balance 
between the technical analyses and due pro-
cess (Figure 2). On the technical side, mem-
bers contribute in areas of their expertise and 
discuss issues of method and evidence. On 
the ‘due process’ side, members ensure stake-
holder interests and views are articulated, 
facilitate sensible interpretation of the tech-
nical ana lysis, assist with ‘value’ judgment 
aspects of the second-stage filter ana lysis 
and help ensure transparency throughout 
the project and assist in the promulgation 
of the results to policy makers. 
In applying the second-stage filter criteria 
the Working Group considers a common 
core of filters (TaBle 1), but the individual decision context can give 
rise to variations (such as the selection of ‘cultural security’ in the 
indigenous component of ACE: Prevention). The main outcome 
of the second-stage filter ana lysis is a table for each intervention in 
which these broader issues are flagged and a qualitative judgment 
made explicit about each of the criterion and its impact. Issues raised 
under the ‘equity filter’ or the ‘acceptability to stakeholders’ filter, 
for example, are briefly described and then a summary entry made 
under a ‘Decision point’ heading (such as ‘not a key issue’; ‘possible 
concerns, needs attention’), which are then all brought together 
under a ‘Policy considerations’ heading that combines both the 
ICER and second-stage filter information (TaBle 2). The second-stage 
filter ana lysis can lead to recommendations about the need for pilots 
prior to widespread implementation, about the need for intervention 
redesign to address equity concerns and/or the need for ongoing 
evaluation/research to improve the evidence base.
Case study of the ACE approach: ACE–Cancer
Background to the ACE–Cancer Study
When ACE-Cancer was undertaken in 2000, Australia Health 
Ministers were advised on strategies to manage nominated priority 
areas by the National Health Priority Action Council (NHPAC). 
The Cancer Strategies Group (CSG) was a standing Subcommittee 
of NHPAC and oversaw the development of the National Cancer 
Strategy. A key element of CSG’s approach to its task was a trans-
parent systematic decision-making process for priority setting and 
strategy development. Earlier in 1997 the National Cancer Control 
Initiative (NCCI) had been launched by CSG [22,62]. It was based 
on the conviction that it should be possible to get a better return 
for expenditure on cancer than was currently being obtained and 
that it was timely to introduce new evidence-based cancer control 
measures. The NCCI had undertaken an extensive consultation 
process of unprecedented breath, which included a questionnaire 
to every organization with interests in cancer control in Australia, 
as well as workshops in each State/Territory to discuss and rank 
30 proposed actions given priority in the questionnaire responses. 
The proposals were ranked using a simple scoring system in which 
each proposal received a score based on summing the participant’s 
response for each of the five criteria (‘size of the problem’, ‘efficacy 
of the action within a 5-year time frame’, ‘likelihood of successful 
implementation’, ‘cost and cost–effectiveness’ and ‘equity’).
The NCCI consultation process was an important first step in 
CSG’s attempts to adopt an explicit approach to priority setting in 
cancer control. Importantly, there was an attempt to relate priority 
judgments to the aims and objectives of cancer control in Australia. 
While the translation of these aims and objectives into the specific 
criteria to rank interventions can be criticized (whether participants 
had a common understanding of the ranking criteria provided, 
whether they gave them similar weight in arriving at their ratings, 
the extent of stakeholder involvement in the development of the cri-
teria and whether the criteria were consistently applied at the various 
stages of the filtering process); the specification of criteria was a clear 
signal of the intent to develop an open, transparent and accountable 
process where the rationale for decisions was specified. 
The NCCI also made an attempt to brief participants in its survey 
of stakeholders and in the State/Territory workshops. This involved 
the provision of descriptive information on healthcare system costs 
and the health burden, which undoubtedly helped participants in 
assessing the ‘size of the problem’. It is questionable, certainly from 
an economic perspective, whether this descriptive information was 
the most appropriate information to guide judgments on resource 
allocation issues. Arguably, the more central issues for resource allo-
cation are information on the effectiveness of the various interven-
tions in reducing the disease burden, the net cost of the interventions 
and whether the interventions represented value-for-money. For cri-
teria other than the size of the problem, participants drew on their 
own knowledge in scoring the various interventions and weighted 
the various criteria as they saw fit in giving an overall score.
Figure 2. Overview of ‘due process’ in Assessing Cost–Effectiveness approach to 
priority setting.
Evaluation process
Intervention selection
• Agree selection criteria
• Agree work program
Technical analysis
• Confirm methods
• Input to research
• Review briefing papers
Second-stage filters
• Agree filters
• Apply filters
• Agree impact of filters
Findings and their dissemination
Due process requirements
• Transparency
• Accountability
• Chance to express views
• Involvement from beginning to end
• Clear roles
• Explicitness of data, analysis and findings
• Review process
• Ownership
Key mechanism for due process
Working Group of Stakeholders
+/- Steering Committee
+/- Technical Advisory Panels
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Subsequent discussion within CSG of the strengths and weak-
nesses of the NCCI priority setting approach included the issue of 
whether or not an economic approach could be utilized as part of 
the decision-making process for developing cancer control priorities 
in the future. In particular, the discussion focused on the clarity of 
the criteria and associated decision rules, and whether the efficiency 
objective had been satisfactorily addressed. In mid 1999, the CSG 
resolved to trial the use of an economic approach as part of its 
review of the priorities determined in the ‘Cancer Control Towards 
2000’ report’ [22]. The trial was to address whether PBMA was an 
appropriate technique to include in the CSG planning process, as 
well as assist with what specific options might be included in the 
next National Cancer Strategy. Note that at this time we had not 
coined the term ‘ACE’ to describe our approach to priority setting, 
which arguably belongs within the PBMA genre.
Overview of the approach adopted
A nine-member Working Party was constituted to cover key stake-
holder interests and take key decisions concerning conduct of the 
study (concerning option selection, concept of benefit, ranking of 
options for change and judgments about the impact of the second-
stage filter). The Working party agreed that there would be: 
A focus on the marginal ana lysis component of PBMA, combined •	
with a clear rationale for the selection of options for change;
An evidence-based approach with a small research team bring-•	
ing together the best available evidence on efficacy/effectiveness 
and undertaking the economic ana lysis;
The choice of the DALY as the measure of health gain;•	
The recognition that ‘benefit’ is broader than just health gain;•	
Adoption of a two-stage approach to the assessment of benefit •	
involving ‘technical’ aspects as the first stage (economic decision 
rule based on ‘cost per DALY’ preferably weighted for distribu-
tive justice) and ‘judgment’ aspects as the second-stage filter 
(level of evidence, equity, size of the problem, acceptability to 
stakeholders, and feasibility of implementation);  
An economic protocol specifically developed for a priority •	
setting context.
The focus on marginal ana lysis (without any program budget 
component) reflected the decision context, a national strategy 
involving multiple jurisdictions and organizations. Along with the 
attention to rigor in the economic modeling, the absence of the 
program budget element distinguishes ACE from other PBMA-
based approaches to priority setting. The focus on marginal ana-
lysis in the case study also allowed the Working Party to assess 
key issues within the time available, such as: 
The potential of ACE to deal with quite divergent options in •	
the disease pathway from prevention through to psychosocial 
care and palliation; 
The potential to measure and weight benefits involving differ-•	
ent dimensions and different levels of evidence in a clear and 
understandable way; 
The potential to integrate the ‘technical’ decision rule based •	
approach of traditional economics with concerns for due process; 
Whether the information provided was valued by members of •	
the Working Party; 
The potential to break down priority setting in a complex deci-•	
sion context into manageable tasks with tractable data and 
resource requirements.
Selection of the options for change
The Working Party reviewed 21 action areas (involving over 
40 individual interventions and/or activities) based on the earlier 
NCCI exercise and classified them into one of five groups using 
a number of criteria:
That a clear and concrete intervention could be specified;•	
That there was sufficient evidence to make an assessment of •	
effectiveness possible;
That both increments (options that involve additional •	
expenditure) and decrements (options that involve reduced 
expenditure) be included;
That options from across the complete disease pathway be •	
included; 
That options be included that test the assessment of both •	
mortality and/or morbidity impacts on health status.
The five groups were: 
Options for change – defined as interventions where suffi-•	
cient evidence existed to indicate that strategies involving 
additional expenditure would be associated with significant 
health gain and strategies involving decreased expenditure 
would be associated with little or no reduction in health 
gain;
Possible options for change – defined as interventions where •	
some evidence existed to indicate that strategies involving addi-
tional expenditure would be associated with health gain and 
strategies involving decreased expenditure would be associated 
with little or no reduction in health gain. These options may 
need more work to specify to a level of precision where they can 
be evaluated;
Monitor developments/liaison•	  – defined as interventions that 
are currently being worked on and/or implemented in another 
context and where it was too early or inappropriate to perform 
an economic evaluation at present;
Research strategies•	  – defined as possible interventions that 
need more research before they can be evaluated; that is, evi-
dence does not yet exist to sustain their efficacy/ effectiveness 
credentials and a clear intervention could not be specified;
Motherhood strategies •	 – defined as those ideas for action that 
were considered to have merit but were too broad and abstract to 
evaluate (and for which specif ic research work was 
not developed).
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The five groups provided a useful way of classifying the large 
number of potential interventions into policy-relevant groupings. 
The intention was to include all those strategies classified as ‘Options 
for change,’ together with some of the ‘Possible options for change.’ 
Briefing papers to guide the Working Party in its assessment were 
prepared by the research team. The briefing papers were quite 
detailed assessments that summarized the available evidence on each 
option. The options chosen for evaluation are listed in TaBle 3.
The concept of benefit
An important dimension to the ACE approach is its potential to 
broaden the concept of benefit to reflect the underlying goals, 
objectives and principles of an organization or program wish-
ing to employ the technique. The Working Party adopted seven 
broad criteria that integrated the objectives of Australia’s cancer 
policy [62] into the measurement of benefit, namely the:
Size of the problem (where can the biggest difference be •	
made?);
Effectiveness (what is the quality of the evidence that the inter-•	
vention works and what health status improvement can be 
anticipated?);
Equity (what is the capacity of the intervention to reduce •	
inequity in health status and the healthcare system);
Efficiency (is the option value for money as reflected by the •	
cost–effectiveness ratio?);
Cost (is the intervention affordable?);•	
Acceptability (acceptance by stakeholders, particularly the •	
general community); 
Likelihood of successful implementation (because of avail-•	
ability of relevant expertise and/or infrastructure, timing 
considerations or other feasibility issues).
It was agreed by the Working Party that these seven criteria 
would be utilized in a two-stage approach to ranking the options. 
In the first stage, options would be ranked by those criteria directly 
related to determining the resources consumed or released by the 
option, together with the size and distribution of the anticipated 
health gain (based on epidemiological and ‘technical’ consider-
ations). In the second stage, the ranking of options would include 
the more pragmatic acceptability/feasibility issues. The first stage 
is characterized by aspects that lend themselves to ‘logical’ deci-
sion-rules, drawn essentially from the health economics discipline. 
The second stage incorporates aspects where it is very difficult 
to develop decision-rules and decisions rest heavily on judgment 
and due process. In its initial consideration of this approach, the 
Working Party included criteria one to five in the first filter, while 
criteria six and seven were in the second filter.
At subsequent discussions aimed at clearly defining the dimen-
sions of benefit, at considering the data collection issues and at 
the specific approach to calculating the cost–effectiveness ratio, 
criteria were moved between the two stages. It was decided that the 
measure of health gain should be the DALY and that the DALY 
should be weighted, if possible, to reflect equity concerns. The 
availability of Australian DALY data [60,63] meant that a common 
unit of measurement was available that captured both morbidity 
and mortality effects across a wide range of diseases and interven-
tion types. This decision meant that criteria two (effectiveness) 
and three (equity) provided the theoretical measure of ‘health gain’ 
and the denominator in the cost–effectiveness ratio. Criterion five 
(cost of the cancer control option) provided the numerator in the 
PBMA cost–effectiveness ratio. Criterion four (efficiency) was 
picked up automatically by the cost–effectiveness ratio (efficiency 
is a relationship between cost and benefits). Two dimensions of 
health benefit previously placed in stage one (‘size of the problem’ 
and the quality of evidence component of ‘effectiveness’) were 
transferred to the second stage of the ranking process during these 
discussions. In relation to the size of the problem, this reflected the 
Working Party’s concern that there might be overlap between this 
dimension and the health gain dimension (because the size of the 
problem would be measured in total DALYs and health gain mea-
sured as the reduction in DALYs). The Working Party preferred to 
pick up the size of the problem criterion more informally in stage 
two of the ranking process, as one of a number of broader policy 
considerations that may alter the ranking of projects from stage 
one based on the technical cost–effectiveness ratios. 
In relation to the quality of evidence component, the Working 
Party considered this to be a factor that was not part of the ben-
efit calculation per se. Rather, it was a factor to be taken into 
account in considering what confidence could be placed in the 
cost–effectiveness ratios, along with other factors in stage two. As 
is the custom in economic evaluation studies, sensitivity ana lysis 
would be conducted wherever feasible to tease out the implications 
of varying the value of key parameters.
The Working Party’s initial intention was for the DALY score 
attributed to each intervention to be weighted for the equity 
implications for four target groups: socioeconomic status, 
Aboriginality, rurality and ethnicity. As a consequence of not 
being able to fully develop and apply equity weights in the time 
available for the study, the Working Party agreed to include 
equity in the second-stage filter. Two dimensions of equity were 
considered. The first was the extent to which the intervention 
might redress any existing health status inequity. The second was 
the extent to which the intervention might, through known or 
likely uptake or access inequalities, give greater health advantage 
to those who already are in a position of health advantage.
The ACE-Cancer results
The results of ACE–Cancer were integrated into the proposed 
National Cancer Strategy, and were distributed for comment 
and feedback by the CSG [62]. They were well received and 
were included in the subsequent National Cancer Strategy. 
The detailed results have also been published separately [48]. 
TaBle 3 provides a summary of the cost per DALY results. The 
interventions are ranked on the basis of the ICERs – either by 
their level of ‘dominance’ or the net cost per DALY ratio. The 
net cost per DALY estimates provided include the point esti-
mate (the result from the primary economic ana lysis) together 
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with the upper and lower bound estimates from the multivari-
ate probabilistic sensitivity ana lysis. While dominant programs 
have strong economic credentials for funding, conversion of 
opportunity cost savings into financial savings should not be 
taken for granted, and for this reason both gross and net cost 
estimates were reported. 
Impact of the second-stage filter analysis
TaBle 2 provides an example of the Working Party’s discussion of 
the second-stage filters. There are a number of ways in which 
the second-stage filters could have been applied. These ranged 
from simple ‘hand-sorting’ of the results by the Working Party 
along the lines adopted by the Commissioners in the Oregon 
Table 3. Ranking of the interventions on the basis of the degree of dominance and net cost per 
DALY results.
Intervention Cost 
(savings)  
$ millions
DALYs 
recovered 
(lost)
Cost per DALY 
(point estimate) 
$
Cost per DALY 
(lower bound) 
$
Cost per DALY 
(upper bound)  
$
Increments
Tobacco control: National Tobacco Campaign
Gross costs (no offsets) 9.0 16,000 840 540 1200
Net costs (or net saving) (39) Dominant Dominant Dominant
Primary prevention of skin cancer (SunSmart on National Basis)
Gross costs (no offsets) 2.5 10,000 250 240 510
Net costs (or net saving) (37) Dominant Dominant Dominant
Fruit & Vegetables Media Campaign
Gross costs (no offsets) 2.5 3600 680 510 16,000
Net costs (or net saving) (12) Dominant Dominant Dominant
Psychosocial care: breast care nurses
Gross Costs (no offsets) 4.9 5200 940 460 1700
Net costs (or net saving) Offsets not 
estimated
Psychosocial care: psychologists for cancer treatment centers
Gross costs (no offsets) 26 4800 5300 1600 5500
Net costs (or net saving) Offsets not 
estimated
National Colorectal Cancer Screening Program (Biennial: ages 55–69 years)
Gross costs (no offsets) 53 3200 17,000 12,500 45,000
Net costs (or net saving) 38 12,000 10,300 40,000
National Colorectal Cancer Screening Program (Biennial: ages 55–74 years)
Gross costs (no offsets) 66 4300 15,000
Net costs (or net saving) 44 10,000
Decrements*
Rationalize the National Cervical Cancer 
Screening Program: change screening 
interval from 2 to 3 years (net saving)
(51) (98) 520,000 160,000 960,000
Rationalize the National Cervical Cancer 
Screening Program: increase age of 
commencement from 18 to 25 years 
(net saving)
(24) (30) 790,000 620,000 960,000
Results presented rounded to two significant figures. 
*The ICERs for decrements can be hard to interpret. Because they are often a combination of potential cost savings, but with potential health loss, the larger the $ 
per DALY, the better the result – you want to see large cost savings but with small health losses. Desirably you want to see dominance – that is, cost savings with no 
health loss.
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process to approaches based on decision theory (such as those 
adopted in some PBMA studies [49,50]). In the event, the filters 
were treated as dichotomous constraints (‘pass’ or ‘fail’) and 
none of the interventions was ruled-out by them. There were, 
nonetheless, some important issues raised that the Working 
Party emphasized should not be ignored. These included atten-
tion to the design of the interventions to offset equity concerns 
(e.g., colorectal cancer screening), the need to strengthen the 
evidence base (e.g., psycho social care by breast care nurses, 
fruit and vegetables) and the way in which proposals might 
be implemented (e.g., cervical cancer screening). The appli-
cation of the second-stage filters clearly involved a judgment 
process that the Working Party endeavored to make as explicit 
as possible by documenting both the process and the content 
of their judgments.
Comparison of the case study & the checklist
Criterion 1: is there clarity in the research question?
A focus on the research question and the objectives of the deci-
sion-maker is a distinctive characteristic of the ACE approach 
and its normative foundation in the Decision-Making School. 
It was given effect through the care taken in defining the study 
perspective, concept of benefit and choice of comparators with 
the Working Group and in the full specification of a study 
protocol. Criterion 1 also covers the recognition given decision 
context and setting, and whether models clarify their relative 
strengths and weaknesses in different choice problems. In this 
regard, the role and limitations of ACE–Cancer were clearly 
specified in both technical and policy reports. More generally, 
the ACE approach is intended to aid decision-making at the 
macro and meso levels within the healthcare system. At these 
levels, the marginal ana lysis possible with the DALY and DCIS 
databases that make ACE tractable, offer quite reasonable guid-
ance. While potentially quite adaptable to variations in decision 
context at the macro and meso levels, its suitability for decisions 
at the micro level would have to be carefully considered. 
Conclusion: the ACE approach actively seeks a well-defined 
research question and is clear about those decision contexts to 
which it is suited.
Criterion 2: is there a clear concept of benefit?
A key component of Criterion 2 is whether the priority setting 
approach has a mechanism or process to define the concept of 
benefit in a way that captures the perspective and objectives of the 
decision-makers. ACE–Cancer illustrates that this criterion is met 
through careful discussion in the Working Party. A key task of 
the ACE research team is to assist the Working Party to establish 
clear connections between their policy objectives, research ques-
tion and the concept of benefit. Once the various dimensions of 
benefit are clarified, the ACE team then takes the Working Party 
through the various steps in defining and measuring the first stage 
‘cost per DALY’ results and the second-stage filters selected. 
Conclusion: the pursuit of a clear concept of benefit is a dis-
tinguishing characteristic of the ACE approach, reflecting the 
adoption of the best features of PBMA.
Criterion 3: is there an acceptable process for generating 
options for change?
Criterion 3 is an important aspect of giving practical effect to the 
economic principle of opportunity cost. In the context of one-off 
studies addressing a single illness or problem, there is usually a 
reasonably limited set of possibilities to consider. In the context 
of studies addressing priority setting, however, there is a very 
broad range of possibilities. Here, the process by which options 
are generated and selected for inclusion becomes an important 
design aspect of the protocol. It is for this reason, together with 
reasons related to the tractability of information collection and 
assessment, that ACE emphasizes: 
A clear process for the development and selection of options  •	
Clear specification of an evaluation protocol specifically •	
developed for the priority setting context 
ACE–Cancer demonstrated two key aspects of the ACE process 
for generating options for change, namely: 
Clarity regarding the steps necessary to generate the options •	
for change, having regard to the specific decision context;  
Clarity about the principles that guide the selection process.•	
Conclusion: ACE has an explicit mechanism for generating 
options for change in a theoretically acceptable and tractable way, 
which pays specific regard to the choice problem and the needs 
of stakeholders. 
Criterion 4: is marginal ana lysis an integral component?
Marginal ana lysis is a fundamental concept of the economic 
approach to problem solving and, as such, has been a foundation 
principle of ACE since its inception. ACE–Cancer illustrates that 
in addition to incremental ana lysis comparing the intervention 
with its ‘current practice’ comparator (‘allocative efficiency’), 
marginal ana lysis of intervention design features (‘technical effi-
ciency’) is also quite feasible. The evaluations of the colorectal and 
cervical cancer screening programs, for example, both illustrated 
that marginal ana lysis of intervention scale/scope (in this case 
screening frequency) and target/user characteristics (age group) 
is not only tractable, but produces accurate results in comparison 
with existing micro studies.
Conclusion: for decision-making at the macro and meso levels, 
ACE has demonstrated a capacity for both sound incremental 
ana lysis (allocative efficiency) and marginal ana lysis across several 
dimensions (technical efficiency).
Criterion 5: are the decision rules clearly specified?
As a general principle, the ACE approach features clear specification 
of the ranking process and associated decision rules, including the 
definition of ‘evidence’. ACE–Cancer illustrates that the ACE first-
stage ranking adopts conventional cost–effectiveness decision rules, 
complemented by probabilistic ana lysis; while the second stage, 
which captures the broader considerations, is more subjective, but 
still explicit. The choice of how the second-stage filters are handled 
is one for the Working Party, having regard to the decision con-
text. In ACE–Cancer this took the form of a simple dichotomous 
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variable (‘pass’; ‘fail’); combined with the specification of decision 
points and policy action to correct specified shortcomings. It is 
worth noting that while the ACE approach places importance on 
clarifying the decision rules, it does not place total reliance on them. 
Due regard has been paid to evidence from empirical experience 
that ritualistic adoption of technical rules simply does not work. At 
best, such an approach is likely to lack support across the range of 
stakeholders necessary to impact on decision-making; at worst, it 
could lead to the rejection of the economic approach to priority set-
ting as introspective and unhelpful to real world problem solving.
Conclusion: both the decision rules, as well as the way in which 
they are utilized in the overall ranking process are clearly specified 
in the ACE approach.
Criterion 6: is the role of judgment clearly specified?
There is clear recognition of the role of judgment in the ACE 
second-stage filter approach, together with acceptance that 
such judgment needs to be made explicit if priority setting is 
not to default back to implicit practices. A weakness in the 
ACE–Cancer study was the lack of in-depth discussion and 
teasing-out of ethical issues. To a large extent this reflected 
the tight time constraint, the established aims and objectives 
of the national cancer control strategy and a common mindset 
amongst participants (mostly epidemiologists, clinicians and 
economists) on how to deal with equity. While a fuller explo-
ration of ethical issues is certainly possible within the ACE 
approach, one suspects that practical constraints will always 
rear their head.
Conclusion: the need for judgment, as well as an explicit process 
for integrating technical information and issues of judgment, is 
clearly recognized in the ACE approach.
Criterion 7: are the data needs tractable?
Data limitations have played a major role in limiting the role and 
credibility of economic approaches to priority setting. The major 
innovation in data management under the ACE approach has 
been the development and/or use of ongoing descriptive databases 
on health expenditure and health status that facilitate incremental 
ana lysis between current practice and multiple options for change. 
The DALY database both assists with estimating the health gain 
(when combined with the efficacy data) and aids judgments about 
‘size of the problem’ (when size is an agreed dimension of benefit). 
Similarly, the DCIS health expenditure database published by the 
Australian Institute of Health and Welfare assists with estimating 
any cost offsets and impact on health sector resource utilization. 
This makes priority setting across multiple interventions a viable 
proposition and limits the data needs of applying ACE to levels 
achievable with a small research team. More specifically, the con-
text specific data needs for ACE are: 
Effectiveness data on the options for change (the existence of •	
which is a prerequisite for option selection); 
Resource utilization data associated with the options for change •	
(based on specifying intervention activity pathways), together 
with routine unit cost assumptions;  
Data needs specific to broader notions of benefit (such as fea-•	
sibility, acceptability and quality of the evidence base) with 
which the Working Party is expected to assist.
Apart from the DALY/DCIS databases, the data needs of ACE 
are made tractable by a number of other features of the approach. 
These include: 
The focus on the development of an evaluation protocol that •	
pays careful regard to the priority setting context; 
The use of a small research team to gather/develop the context •	
specific databases (the case study was implemented with a 
small research team equivalent to two or three full-time 
research staff ); 
The focus on option selection so that a comprehensive but •	
manage able number of interventions are assessed at any 
one time;  
The potential for ACE to be institutionalized as a routine part •	
of the priority setting/planning process, with connections pos-
sible to other pre-existing data sets (such as data holdings on 
intervention efficacy; manuals of resource unit costs and disease 
incidence/prevalence/risk factor data sets.
Conclusion: ACE provides an approach to priority setting in 
which the data needs are made tractable.
Criterion 8: is the need for ‘due process’ recognized?
The extensive involvement of stakeholders within the ACE 
Working Party potentially meets important aspects of this cri-
terion. The extent and nature of this involvement separates the 
ACE Working Party from the more routine project-steering com-
mittees and/or advisory committees that are a common feature of 
the health sector. Key issues that arise, however, include: 
The extent to which all stakeholder interests are adequately •	
represented (particularly the consumer perspective); 
The extent to which the decision-making processes adopted •	
within the Working Party are regarded as ‘fair and reasonable’ 
(explicit, consistent, principled, democratic and based on relevant 
and credible information);  
The extent to which individual participants see themselves as •	
having had an effective voice. 
While there is certainly a conscious attempt to achieve these 
attributes, as demonstrated by ACE–Cancer, clearly there is poten-
tial for the performance of the ACE model to vary from application 
to application. 
One aspect of this complex issue is the way in which group 
decisions/scores are taken, particularly whether by seeking simple 
averages or by group consensus after informed discussion. While 
an issue of judgment, our clear preference after trialing both 
approaches in several ACE studies, is for the group consensus 
approach. Participants of ACE studies conducted to date sup-
port this view. Other difficult issues include how to facilitate 
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effective consumer representation and how to capture the difficult 
issues surrounding equity and ethics. While participants in the 
ACE–Cancer study were very supportive of the ACE approach 
and saw it as a ‘quantum’ improvement in the way in which deci-
sions were taken, no member believed we yet had the process ‘just 
right’. Further work will be required to fine-tune the process, 
aided by empirical feedback by participants and those affected 
by the decisions.
Conclusion: the ACE approach has the potential to meet the due 
process criterion, but there is still room for improvement and careful 
ongoing monitoring of performance on this criterion is essential. 
Criterion 9: do the measurement methods demonstrate 
appropriate rigor?
All ACE studies, including ACE–Cancer, are underpinned by a 
full economic protocol and publication of research methods. The 
evaluation protocol ensure that, wherever feasible, standardized 
evaluation methods are applied across all options assessed (with 
any exception clearly documented); that sensitivity ana lysis of key 
parameters is undertaken using multivariate probabilistic sensitivity 
ana lysis; that a standardized approach is taken to data collection and 
ana lysis and that careful regard is paid to the quality of evidence.
Conclusion: the ACE approach, both in design and application, 
demonstrates rigor in the measurement of costs and benefits.
Criterion 10: reporting/implementation
Criterion 10 asks whether priority setting models report results in 
a way that meet the concerns of decision-makers. The steps that 
underlie the ACE approach (particularly the focus on aims and 
objectives, on a clear concept of benefit, the second-stage filter 
ana lysis and on meaningful discussion of the results and their 
implementation) ensure that this criterion is taken very seriously. 
The full report of ACE–Cancer [48] illustrates the potential for 
reporting of a range of issues of concern to decision-makers. This 
includes guidance on what weight can be placed on the results in 
terms of the strength of evidence and rigor of the evaluation meth-
ods, as well as broader issues such as equity implications, feasibil-
ity of implementation, acceptability to stakeholders, importance 
of the problem addressed and financial implications.
Conclusion: the ana lysis and reporting of results under the 
ACE approach ensures that issues of concern to decision-makers 
are addressed.
Overview of the ACE-Cancer performance
The merit of the ACE approach was discussed on several occa-
sions in the various meetings of the Working Party. The clear 
view that emerged from these discussions was that while there 
were aspects of the ACE methods and process that could be 
criticized and/or improved upon, the approach trialed repre-
sented a “quantum leap forward in the quality of information 
available for decision-making” [Pers. Comm.; Mark Elwood, Working 
Party Member] [48]. Both the information base (the briefing papers) 
together with the process by which the deliberative judgments 
were achieved, were viewed in a very positive light. More spe-
cifically, the use of an evidence-based approach facilitated by 
a suitably qualified research team assembling information on 
efficacy and efficiency was strongly supported. The type and 
quality of information, the method of its collection and pres-
entation and the clarity as to its intended use were viewed as 
important improvements over the NCCI priority setting process 
of 1997. The emphasis of the ACE approach on achieving a clear 
concept of benefit was also strongly supported. While members 
saw this discussion and its translation into clear measurement 
techniques as a challenging process, it was nonetheless accepted 
as an important task. Members of the Working Party concluded 
that the ACE process performed well and showed promise of 
being an important addition to the strategic planning process 
for cancer control in Australia. 
This optimism was enhanced by three additional consider-
ations. First, the feedback on the Draft National Cancer Strategy 
Report released for public consultation, included very positive 
feedback on the ACE input from senior members of the cancer 
research community (such as ‘should serve as a model for prior-
ity setting in other health areas’; ‘decision-making and priority 
setting techniques are impressive’ and ‘inclusion of economic 
ana lysis very valuable’). Second, a positive assessment of the 
cancer control case study by an independent review of priority 
setting models for health [59] and third, the funding of addi-
tional major applications of the ACE approach in cardiovascular 
disease and mental health within a year after completion of the 
ACE–Cancer study.
Other ACE work & reflections from the ACE experience
Reflecting back across the ACE studies completed to date and/or 
currently in progress (TaBle 1), there are a number of observations 
to offer. We have grouped these under three headings: 
Observations regarding acceptability and impact of ACE•	
Observations regarding the technical ana lysis component •	
of  ACE 
Observations regarding the due process component of ACE•	
We have also reflected on to what extent any difficulties 
encountered are resolvable.
Observations regarding acceptability & impact of ACE approach
The use of an evidence-based approach, facilitated by a suitably •	
qualified research team assembling information on effective-
ness, cost-effectiveness and the second-stage filters, has been 
strongly supported by all ACE Working Groups;
In all ACE studies, irrespective of decision context and funding •	
source, there has also been strong endorsement of the relevance 
and usefulness of the second-stage filter ana lysis to complement 
findings based on the ICERs; 
While stakeholders support the second-stage filter ana lysis, they •	
have still expected technical rigor in the ICERs in order to ‘trust 
the arithmetic’. Technical rigor and due process have been seen 
as complements, not substitutes;
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Where studies have been directly funded by government, •	
policy impact was higher, particularly when undertaken to 
inform specific strategic plans (as with ACE–Cancer). The 
drawback of decision contexts involving direct use in govern-
ment policy, however, was shorter timeframes with less scope 
for more rigorous methods. We do not see this situation 
changing in the near future;
Where studies have been grant-funded over longer timeframes, •	
technical sophistication has improved, but the policy impact is 
indirect and more diffuse, often reliant on dissemination 
through the literature and/or conference presentations (e.g., 
ACE–Heart disease; ACE–Prevention). Again this situation is 
unlikely to change;
Government-funded studies that were only loosely connected •	
to policy development (important information-gathering 
exercises but not undertaken to help resolve specific questions) 
also struggled to achieve visible direct policy or clinical 
impacts (e.g., ACE–Mental health), but their indirect impacts 
were more substantive. In ACE–Obesity, for example, the 
Departmental project leader has been asked to supply infor-
mation for various policy processes that link back to the 
ACE–Obesity research. Examples include the banning of 
fizzy drinks in schools and informing the national debate 
about further restricting advertising to children. This is 
encouraging for future collaborations between government 
and ACE researchers.
Observations regarding the technical ana lysis
A key challenge has been to find a level of economic modeling •	
that is sufficiently rigorous to achieve confidence in the results, 
achievable within the priority setting context where multiple 
interventions need to be assessed, while being transparent and 
easy-to-understand for policy makers. The ACE team is still 
resolving this challenge and will use case studies where differ-
ent models are applied to the same decision context to further 
explore the issues and impacts;
A second key challenge has been finding satisfactory ways of •	
combining the ICERs into policy advice about intervention 
packages. While technical solutions are available that reflect 
the ICERs (such as expansion paths), resolving how to com-
bine the ICERs with the second-stage filter information is 
more challenging. The ACE team is still researching this 
issue;
The available evidence base in some research areas (such as •	
obesity prevention) is also an issue. Evidence impacts on ACE 
methods at three points: first, at the point of selecting the 
interventions for assessment (there must be sufficient evidence 
to be able to clearly specify and model the effects of the inter-
vention); second, in the sensitivity ana lysis (less evidence leads 
to wider and sometimes arbitrary uncertainty intervals) and 
third, at the policy conclusion stage in terms of what level of 
confidence can be placed in the ICERs and the trade-offs 
between ICERs and broader factors. For each application of 
the ACE approach, therefore, careful consideration has had to 
be given to clearly defining the concept of ‘evidence’ with 
stakeholders, including a classification system to grade addi-
tional sources of evidence, such as ‘indirect evidence’, ‘parallel 
evidence’ and ‘epidemiological modeling based on a range of 
evidence sources’; 
It has been easier, although still challenging, to apply our stan-•	
dardized methods in ACE studies that focused on a single 
disease or a single risk factor, than in those studies involving 
multiple diseases and/or risk factors, with disparate data 
sources. This supports the empirical evidence from a number 
of studies that vertical priority setting is easier to accomplish 
that horizontal priority setting;
Related to this, data tractability remains a challenging problem •	
for technical approaches that seek to analyze multiple diseases 
and risk factors. In Australia we are fortunate to be able to draw 
on existing databases that describe the epidemiology of diseases 
and summarize the disease burden and current healthcare 
expenditure. Such databases can be very useful in calculating 
the health benefit and potential cost offsets across multiple 
diseases/risk factors in a consistent way;
Approaches like ACE that include rigorous technical ana lysis •	
across multiple disciplines require skilled researchers in health 
economics and epidemiology. ACE has benefited from grant 
support in this regard (as opposed to reliance on commissioned 
work), because training and up-skilling of research staff 
(including PhD scholarships) can be specified as an important 
component of the grant program;
Finally, agreeing clear criteria to underpin the selection of •	
options of change has been important both in theoretical terms 
(focusing on ‘opportunity cost’) and in policy terms (to ensure 
relevance and commitment).
Observations regarding due process
Stakeholders have always been strongly supportive of linking •	
broad policy objectives to the assessment through the second-
stage filters. Selecting the filters has worked well, although 
avoiding overlap has on occasions been challenging. Defining 
the filters clearly to avoid confusion in the discussions has been 
a little tougher (e.g., defining concepts such as ‘equity’ or ‘cul-
tural security’), but never insurmountable. Finding data to 
inform the second-stage filter discussion has often proven dif-
ficult and this aspect of the ana lysis is inevitably reliant on the 
professional judgment of the stakeholders. This situation is not 
likely to change;
While there are technical ways of incorporating the second-•	
stage filters into the ICERs (using decision theory), most ACE 
Working Groups have not been attracted to this technical 
option and have preferred the clarity and simplicity of the 
two-step process;
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In ACE studies to date, game playing has not been a problem •	
and consensus conclusions following deliberative discussion 
have been adopted in all studies. Confidential voting has not 
been requested or applied in any ACE study;
While lay people have been involved in some of our studies •	
(e.g., ACE–Cancer, ACE–Mental health and Community 
Health Centers study), this has always been a challenging issue 
owing to the steep learning curve involved for lay people to get 
across the technical component of the ACE work. This issue is 
likely to remain while ever priority setting exercises are run on 
tight budgets with tight timelines.
Expert commentary & five-year view
Despite some progress in recent times, explicit priority set-
ting along the lines involved in ACE is not commonplace. 
Management, whether in government or elsewhere, will need 
time to trust explicit approaches to priority setting, particularly 
if they are time and resource intensive. For many, explicit pri-
ority setting is not part of the current organizational culture. 
To expect managers, working in an often reactive and stressful 
environment, to immediately adjust their practices to incorpo-
rate an external framework, no matter how impeccable its logic, 
is unrealistic. This is particularly so when that framework has 
implications for current financial reporting practice (e.g., pro-
gram structure and associated cost centers); for current data 
collections (e.g., the collection of activity and outcome data); 
for research activity (e.g., establishing the evidence base) and 
the visibility of decisions. There needs to be recognition that 
explicit approaches to priority setting require infrastructure, a 
long-term commitment from senior management and the cour-
age to confront vested interests. Decision-makers need to have 
confidence, therefore, not only in the technical results, but also 
that the policy recommendations include a consideration of the 
broader factors that impinge on them. 
ACE has shown that there is no inherent conflict between 
action to provide more and better information on the costs and 
outcomes of different interventions and work to strengthen the 
processes for debating that information and arriving at judgments 
on priorities. The key question will remain the extent to which 
technical appraisal and due process is used and the respective 
emphasis on these different approaches. Key issues in finding this 
balance will include:
Closer working with government to generate trust, maintain •	
relevance and direct knowledge transfer;
Finding the correct level of economic modeling, balancing •	
rigor, timeliness and user friendliness;
Finding the balance in reporting formats between declaring •	
weaknesses in the methods and data sets and not undermining 
the whole endeavor (not letting ‘perfection’ become the enemy 
of the ‘simply good’);
Achieving data tractability through large data bases that sum-•	
marize the current health burden and health expenditure across 
all diseases/risk factors;
Improving the surveys and routine data collection systems that •	
underpin the epidemiological estimates of disease/risk factor 
incidence and prevalence (reducing the reliance on self-report 
in generic health surveys);
Developing the evidence base on intervention efficacy/•	
effectiveness;
Careful consideration of the definition of ‘evidence’ and its •	
incorporation into all aspects of the ana lysis; 
Broadening the appeal of studies in the health sector (to •	
Departments of Finance and Treasury) by incorporating 
broader production effects in the general economy. 
Many authors and reviewers of international experience endorse 
the call for multidisciplinary research. Australian experience has 
demonstrated that consensus approaches founded in behavio-
ral science have been well regarded by participants. While these 
approaches have important limitations from an economic per-
spective, their success in consensus building highlights the poten-
tial for an interdisciplinary approach that draws on the respec-
tive strength of each discipline. Similarly there are a number of 
models that demonstrate the significant potential for cooperative 
research between economics and epidemiology. The nature of the 
collaboration and the disciplines involved will depend, of course, 
on the research issue.
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Key issues
There are no simple solutions to the challenges posed by priority setting. Complexity is inherent in the range of stakeholders involved, • 
the various levels at which decisions are taken and the importance attached to ethical values and principles. 
There are a wide variety of approaches to priority setting available, offered from a range of disciplines (economics, epidemiology, • 
behavioral science and philosophy). A useful step in assessing these various approaches is to reflect on the question of what constitutes 
an ‘ideal’ approach to priority setting. 
An important contribution of this article is to provide a broadly based checklist based on four rationales, namely: guidance from • 
economic theory, the lessons from empirical experience with priority setting, guidance from ethics and social justice and the needs 
of decision-makers.
The Assessing Cost–Effectiveness (ACE) approach to priority setting meets the ten criteria set out in the checklist better than any of the • 
other approaches reviewed. ACE offers a credible way of achieving both technical rigor and the practical inclusion of broader issues of 
concern to decision-makers.
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